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Next-Generation Sequencing Sheds Light on the
Natural History of Hepatitis C Infection in Patients
Who Fail Treatment
Tamer Abdelrahman,1 Joseph Hughes,1 Janice Main,2 John McLauchlan,1 Mark Thursz,2 and
Emma Thomson1,2
High rates of sexually transmitted infection and reinfection with hepatitis C virus
(HCV) have recently been reported in human immunodeficiency virus (HIV)-infected
men who have sex with men and reinfection has also been described in monoinfected
injecting drug users. The diagnosis of reinfection has traditionally been based on direct
Sanger sequencing of samples pre- and posttreatment, but not on more sensitive deep
sequencing techniques. We studied viral quasispecies dynamics in patients who failed
standard of care therapy in a high-risk HIV-infected cohort of patients with early HCV
infection to determine whether treatment failure was associated with reinfection or
recrudescence of preexisting infection. Paired sequences (pre- and posttreatment) were
analyzed. The HCV E2 hypervariable region-1 was amplified using nested reverse-
transcription polymerase chain reaction (RT-PCR) with indexed genotype-specific pri-
mers and the same products were sequenced using both Sanger and 454 pyrosequencing
approaches. Of 99 HIV-infected patients with acute HCV treated with 24-48 weeks of
pegylated interferon alpha and ribavirin, 15 failed to achieve a sustained virological
response (six relapsed, six had a null response, and three had a partial response). Using
direct sequencing, 10/15 patients (66%) had evidence of a previously undetected strain
posttreatment; in many studies, this is interpreted as reinfection. However, pyrosequenc-
ing revealed that 15/15 (100%) of patients had evidence of persisting infection; 6/15
(40%) patients had evidence of a previously undetected variant present in the posttreat-
ment sample in addition to a variant that was detected at baseline. This could represent
superinfection or a limitation of the sensitivity of pyrosequencing. Conclusion: In this
high-risk group, the emergence of new viral strains following treatment failure is most
commonly associated with emerging dominance of preexisting minority variants rather
than reinfection. Superinfection may occur in this cohort but reinfection is overesti-
mated by Sanger sequencing. (HEPATOLOGY 2014;00:000-000)
A
n estimated 185 million people have been
infected with hepatitis C virus (HCV) around
the world and more than 350,000 people die
from HCV-related liver diseases every year.1 Shared
routes of transmission mean that human immunodefi-
ciency virus (HIV)/HCV coinfection is common,
affecting at least 4-5 million individuals.2 Advances in
treatment options for HCV are rapidly emerging; such
direct-acting antiviral (DAA) therapies are genotype-
and subtype-specific and therefore an understanding of
the total population of HCV variants present in an
infected host is likely to be of increasing importance
in order to identify the most appropriate treatment for
infected individuals.3
In the last decade, an increase in the incidence of
acute HCV infection among HIV-infected men who
have sex with men (MSM) in Europe, Australia, and
the United States has led to a substantial number of
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studies on this new public health problem.4 Descrip-
tions of HCV reinfection in this group have been
widely reported but have not employed deep sequencing
or detailed phylogenetic analysis.5,6 We have previously
shown that HCV in HIV-infected MSM is commonly
associated with the presence of multiple strains in indi-
vidual infected patients (10% with multiple genotypes).
Such variation occurs as a consequence of the transmis-
sion of multiple HCV strains either around the time of
initial infection or sequentially over time. We hypothe-
sized that reinfection rates following treatment may be
overestimated by standard sequencing techniques due to
a lack of detection of varying dominance of minority
variant strains present at the onset of infection.3
We used viral load monitoring and deep sequence
analysis to dissect the different causes of treatment fail-
ure using pre- and posttreatment plasma samples taken
from patients who failed standard of care therapy with
24-48 weeks of pegylated interferon alpha (IFN) and
ribavirin (RBV).7 Sustained virological response (SVR)
rates are typically lower in this group (59-71%) than
in HCV monoinfected patients (98%).8,9 We used
detailed phylogenetic analysis of pre- and posttreat-
ment variants obtained using Sanger sequencing, clonal
analysis, and next-generation sequencing (NGS) to dif-
ferentiate relapse from reinfection.
Materials and Methods
Patient Cohort
In all, 99 patients with HIV were treated for acute
HCV infection between 2005 and 2012 in a single cen-
ter (the St Mary’s Acute Hepatitis C Cohort). Pegylated
IFNa and RBV were administered for 24-48 weeks
according to British HIV Association guidelines.7 A
group of 15 patients failed to respond to treatment,
including six null responders, three partial responders,
and six relapsers. Paired samples from each patient pre-
and posttreatment were analyzed. Informed consent in
writing was obtained from each patient and the study
protocol conformed to the ethical guidelines of the
1975 Declaration of Helsinki and ethical approval was
granted by the Riverside Research Ethics Committee.
Definitions
We used viral load monitoring and phylogenetic
analysis to define distinct groups of patients.
Patient Groups Based on Viral Load Monitor-
ing. Sustained virological response: undetectable HCV
RNA 24 weeks after the end of treatment. Null response: a
reduction of less than 2 log10 in HCV RNA by week 12
of treatment. Partial response: a reduction of 2 log10 or
more in HCV RNA by week 12, but failure to achieve an
undetectable viral load. Relapse: an undetectable HCV
RNA level at the end of treatment but reelevation of viral
load within 24 weeks after the end of treatment.
Patient Groups Based on Phylogenetic Analy-
sis. Sequences obtained from paired samples pre- and
posttreatment were considered similar or different
based on two criteria, 1) phylogenetic signal, mono-
phyletic or nonmonophyletic lineage; 2) genetic dis-
tance >10% between sequences; this was calculated as
the pairwise distance between aligned sequences.
Persistent infection: the presence of at least one variant
present in the pretreatment sample persisting after exposure
to treatment. This could be associated with new domi-
nance; the outgrowth of a minority strain present in the
pretreatment sample, or the presence of a new variant repre-
senting superinfection or a preexisting undetected variant.
Reinfection: the presence of new variant(s) in the
posttreatment sample with no evidence of similar pre-
existing strains.
Amplification and Sequencing of the E2 HVR-1
Region
Plasma stored at 280C was thawed on ice. RNA was
extracted using a QIAamp Viral RNA kit (Qiagen) as
recommended by the manufacturer. cDNA synthesis was
performed using SuperScript III Reverse Transcriptase
(Invitrogen). Amplification of a 220 basepair (bp) region
including the E2 hypervariable region-1 (HVR-1) was
carried out using nested polymerase chain reaction
(PCR) using a combination of genotype-specific primers
as previously described.10 The HVR-1 has the highest
degree of heterogeneity within the HCV genome and can
therefore be used to differentiate HCV strains. PCR
products were run on a 2% agarose gel containing SYBR
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safe DNA gel stain (Life Technologies) with lane markers
and a 100-bp small fragment ladder (Fermentas). DNA
bands were visualized under ultraviolet light and bands of
appropriate size were extracted and purified using a Gen-
eJet extraction kit (Fermentas). PCR product was sent for
direct Sanger sequencing and was also cloned into the
TOPO-4 vector (Invitrogen, Paisley, UK) and sent to
Beckman Coulter Genomics for miniprep and Sanger
sequencing in 96-well plates.
Sanger Sequencing Analysis
Chromatograms were checked for miscalled nucleo-
tides by visual inspection of chromatograms using Bio-
Edit v. 7.1.3 software. Sequences were aligned using
MUSCLE11 and maximum likelihood phylogenetic
trees constructed using MEGA 5.0.12 Trees were gen-
erated following gap exclusion and corrections for
multiple substitutions were performed using the
Kimura two-parameter substitution model.13 The sta-
tistical robustness and reliability of the branching order
within each phylogenetic tree was confirmed by boot-
strap analysis using 1,000 replicates. Bootstrap values
>70% were considered reliable. Sequences generated
as part of this study have been submitted to GenBank.
Next-Generation Sequencing of Pretreatment Samples
Primer binding sites for deep sequencing as well as
multiplex identifiers (MIDs) for sample bar coding
were synthesized into the inner primer design to create
fusion primers compatible with the 454 platform.
Amplicons were diluted to create a multiplexed library
with equimolar concentrations. The library was sent
for 454 FLX second-generation sequencing by Beck-
man Coulter Genomics, USA.
Sequences were de-multiplexed using a custom Perl
script that identified the forward and reverse barcodes
allowing one mismatch in the reverse barcode. All
scripts are available on Github (https://github.com/
josephhughes/HCVtoolbox). Each read was compared
to a reference set of sequences from the Los Alamos
HCV database and was quality checked by comparing
it in a pairwise alignment to the best reference match.14
A read was excluded from the dataset if it had muta-
tions relative to the reference below a Phred score of
25, and if there was only a single copy of the read. The
final set from each patient was then aligned against the
complete reference set of sequences using MAFFT.15 In
order to estimate the error rate of our sequencing
approach, a plasmid containing HVR-1 was sequenced
using a 454 approach following endpoint dilution.
All valid reads were clustered using CD-HIT with a
parameter of similarity of 90% to assign different variants
detected in each sample.16 These variants were aligned
with posttreatment variants detected by clonal analysis
and reference sequences of different genotypes from the
Los Alamos HCV database using MUSCLE11 and maxi-
mum likelihood phylogenetic trees were constructed using
MEGA 5.0 as described above.12 All sequences generated
were submitted to the European Nucleotide Archive
(ENA), study accession number PRJEB4613.
Results
Error Rates. An alignment of control HVR-1 plas-
mid pyrosequences resulted in a mean depth of 16,918
at each nucleotide site. Assuming that the most fre-
quently found sequence was the real sequence, we calcu-
lated the error rate as 0.002 per bp. This error included
any error in the sequencing and during PCR. The error
rate of the proof-reading enzyme Phusion High-Fidelity
DNA Polymerase used in all PCR reactions was calcu-
lated as <7.1 3 1026 nucleotides/cycle/site.
Viral Dynamics in Paired Serum Samples Deter-
mined by Direct Sequencing, Clonal Sequencing,
and NGS. Pairwise distance between strains (for NGS
and clonal analysis, this was calculated between the
most similar pretreatment and posttreatment strains)
was significantly higher using direct sequencing than
NGS (mean 0.221 versus 0.026, respectively;
P5 0.0002). Using direct sequencing, evidence of a
new variant was detected in 10/15 (66%) patients post-
treatment (Supporting Fig. 1). However, when NGS-
derived pretreatment sequences were compared with
clonal sequence analysis of posttreatment samples,
100% of patients had evidence of a similar variant pres-
ent in pre- and posttreatment samples. A new variant
(in addition to a preexisting variant) was detected in
posttreatment samples in 6/15 (40%) patients (Table 1;
Supporting Fig. 2A-C). This was a minority variant in
three patients and a majority variant in three patients.
Mixed Strain Infections. All patients had evidence
of multiple strain infection with 2-6 variants of geno-
type 1a. Seven patients had evidence of mixed subtype
or genotype infection at baseline; six patients had two
subtypes (1a and 1b) and one patient had a mixed
genotype infection (1a and 4d). Minority strains that
emerged following therapy ranged from 3% to 13% of
the viral population in pretreatment samples, and
reached up to 75-100% of the total viral population
in posttreatment samples (Table 1).
Patient Groups. In null responders (six patients:
P63, P38, P67, P81, P112 and P118; Fig. 1; Supporting
Figs. 3-7), mixed subtype infection (1a/1b) at the outset
was detected in 5/6 patients, and the sixth patient had
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multiple variants of genotype 1a. All six patients had evi-
dence of a similar strain present pre- and postinfection.
Three patients (P63, P67, P112) had persistent infection
with the same pretreatment dominant strain, one patient
(P118) had new dominance of a preexisting minority var-
iant, and two patients (P81, P38) had evidence of a new
variant in addition to preexisting strains (minority and
majority posttreatment variant, respectively).
In all partial responders (P31, P21, P105; Fig. 2;
Supporting Figs. 8, 9), multiple variants were present
(3, 4, and 5 variants, respectively). One patient had
persistent infection with the same pretreatment variant
(P31) and two patients (P21, P105) had persistent
infection with evidence of a new previously unidenti-
fied strain in the posttreatment sample (minority and
majority variants, respectively).
In relapsers (six patients: P57, P141, P76, P75,
P101, P131; Fig. 3; Supporting Figs. 10-14), all
patients had evidence of persisting variants and four of
them (P101, P57, P76, P141) showed new dominance
of preexisting minority strains. Two patients had evi-
dence of new previously undetected strains; in one case
the previously undetected variant became dominant in
the posttreatment sample (P131) while in another
patient (P75), the undetected variant was a minority
strain (29%) on top of a preexisting variant (71%).
Discussion
There have to date been few detailed studies of
HCV infection and reinfection in the setting of antivi-
ral treatment in HIV-infected MSM. Behavioral stud-
ies have shown that HIV-infected patients with acute
HCV are likely to be at high risk of reexposure and
therefore the presence of switching genotype or viral
rebound is often assumed to be secondary to reinfec-
tion.17,18 Through detailed virological characterization
using next-generation pyrosequencing in a prospec-
tively sampled cohort, our study provides a new
insight into viral dynamics during treatment failure in
this cohort of patients.19,20
The reported prevalence of multiple strain infection
in HIV and HCV coinfected subjects has been
reported in up to 40% of those infected.10 Such esti-
mates may be low, however, because screening methods
used in most studies lack sensitivity for the detection
of viruses present at low levels. Moreover, transient
infections may be missed if sampling is infrequent. We
used direct sequence analysis, clonal analysis, and NGS
of samples obtained pre- and posttreatment to investi-
gate whether treatment failure occurred most com-
monly due to viral recrudescence or reinfection.
In contrast to other studies, our findings indicate
that multiple infections are common in early HCV
infection, reaching 100% in our cohort, with a mean
of 3.8 variants present prior to treatment.21 Other
studies may not have detected multiple strains because
of limited sampling or because of primer selection
bias, for example, employing only genotype 1- and 2-
specific primer sets; deep sequencing has higher sensi-
tivity in detecting minor variants that are missed by
Table 1. Characteristics of Viral Population Dynamics and Treatment Response in Patients With Treatment Failure
ID Clinical Outcome
Pairwise Distance
(Sanger)*
Pairwise Distance
(NGS)y
New
Dominancez
New
Variants§ Final Conclusion
P38 Null response 0.19 0.08 - 1 Persistent infection (New variant detected)
P63 Null response 0.03 0 - 0 Persistent infection
P67 Null response 0.04 0.04 - 0 Persistent infection
P81 Null response 0.48 0.06 13% 1 Persistent infection (New dominance
and new variant detected)
P112 Null response 0.17 0.01 - 0 Persistent infection
P118 Null response 0.47 0.01 3% 0 Persistent infection (New dominance)
P21 Partial response 0.27 0 NA 1 Persistent infection (New dominance
and new variant detected)
P31 Partial response 0.08 0.08 - 0 Persistent infection
P105 Partial response 0.46 0 - 1 Persistent infection (New variant detected)
P75 Relapse 0 0 - 1 Persistent infection (New variant detected)
P76 Relapse 0.24 0.05 3.2% 0 Persistent infection (New dominance)
P101 Relapse 0 0 - 0 Persistent infection
P57 Relapse 0.33 0.03 9% 0 Persistent infection (New dominance)
P131 Relapse 0.27 0.05 - 2 Persistent infection (New variant detected)
P141 Relapse 0.24 0.01 3.9% 0 Persistent infection (New dominance)
*Outcome is determined by comparing consensus sequence of pre- and posttreatment samples using Sanger sequencing.
†Pairwise distance is the pairwise distance between the similar variants in paired samples where a new dominance of pre-exisiting minority strain was noticed.
‡New dominance is the frequency of the new dominant variant of the posttreatment sample detected in the pretreatment sample.
§Number of new variants detected in posttreatment sample.
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Fig. 1. Comparison of viral complexity in paired serum samples (pre- and posttreatment) in patient -P63, Null response, Persistent infection.
(A) A Maximum likelihood tree was constructed using nucleotide sequences from paired samples and selected HCV reference sequences for the
Los Alamos HCV database. A total of 4 (A-D) HCV variants detected. The analysis included; 25 clonal sequences (posttreatment), and 46156
reads derived from 454 pyrosequencing (pretreatment). There were a total of 183 positions in the final dataset. (B) Bubble chart of the fre-
quency of each variant (A-D) in pre- and posttreatment samples. (C) Pairwise distance between the most similar variants in the pre- and post-
treatment samples (p-distance).
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Fig. 2. Comparison of viral complexity in paired serum samples (pre- and posttreatment) in patient -P31, Partial response, Persistent infec-
tion. (A) A Maximum likelihood tree was constructed using nucleotide sequences from paired samples and selected HCV reference sequences
for the Los Alamos HCV database. A total of 4 (A-D) HCV variants detected. The analysis included; 35 clonal sequences (posttreatment), and
36422 reads derived from 454 pyrosequencing (pretreatment). There were a total of 183 positions in the final dataset. (B) Bubble chart of the
frequency of each variant (A-D) in pre- and posttreatment samples. (C) Pairwise distance between the most similar variants in the pre- and post-
treatment samples (p-distance).
6 ABDELRAHMAN ET AL. HEPATOLOGY, Month 2014
Fig. 3. Comparison of viral complexity in paired serum samples (pre- and posttreatment) in patient -P57, Relapse, Persistent infection with
new dominance of pre-existing minority variant. (A) A Maximum likelihood tree was constructed using nucleotide sequences from paired samples
and selected HCV reference sequences for the Los Alamos HCV database. A total of 3 (A-C) HCV variants detected. The analysis included; 20
clonal sequences (posttreatment), and 23042 reads derived from 454 pyrosequencing (pretreatment). There were a total of 183 positions in the
final dataset. (B) Bubble chart of the frequency of each variant (A-C) in pre- and posttreatment samples. (C) Pairwise distance between the
most similar variants in the pre- and posttreatment samples (p-distance).
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conventional methods. In addition, it is also possible
that our cohort harbor more HCV strains, as patients
that have failed treatment may have a more diverse
quasispecies.
The detection of multiple viral strains at a single pre-
treatment timepoint in patients with acute HCV could
be the result of simultaneous transmission, or superin-
fection within a short timeframe. Mixed HCV infection
has previously been reported as being transient, as a
consequence of a more effective immune response
against one viral strain, or competition between variants
with the fitter strain having an advantage over others.22
We found that although a dominant variant was present
in most samples, mixed infection was present at both
timepoints examined in the majority of our patients,
and variation in quasispecies composition was common
over time, suggesting that certain strains may have been
positively selected during treatment. Strikingly, we
found preexisting strains present in 100% of patients
sampled following treatment failure. This finding sug-
gests that clearance and reinfection is not the common-
est mechanism of treatment failure in this cohort.
This is in keeping with a lack of evidence of reinfec-
tion in other cohorts of HIV-infected patients with
chronic HCV, although in this acutely infected cohort,
evidence of genotype or subtype switching was seen
more frequently.23 This could be attributed to the sen-
sitivity of deep sequencing in differentiating variants of
the same genotype compared to Sanger sequencing or
PCR-based hybridization assays.
The presence of previously undetected variants in
40% of posttreatment samples could represent superin-
fection, but could also represent variants present below
the threshold of detection using pyrosequence analysis.
This phenomenon occurred in those with a null
response, partial response, and following relapse.
In null responders, all patients had a persistent strain
pre- and posttreatment and three of six patients had a per-
sistent variant that remained dominant throughout. Emerg-
ing dominance of a preexisting minority variant occurred
in two patients, one of whom had evidence of a previously
undetected minority variant following treatment. In the
remaining patient, a new majority variant emerged after
treatment in addition to a persistent minority variant. This
could represent superinfection or emergence of a strain
below the limit of detection of pyrosequencing (in this
case, 46,755 sequence reads were analyzed pretreatment).
In partial responders, we found evidence of persis-
tent variants in all three patients. In two patients (P21
and P105), the dominant variant cleared following
treatment, while the third patient (P31) cleared a vari-
ant representing 44% of the pretreatment viral popula-
tion. In all cases, clearance was concurrent with a fall
in viral load during treatment. A previously undetected
variant was present in two of three patients in post-
treatment samples. Such variants may have been posi-
tively selected from minority variants undetected in
the pretreatment sample or could represent superinfec-
tion during treatment.
In patients with viral relapse, all patients had evi-
dence of a preexisting variant present in posttreatment
samples. Three patients (P57, P76, and P141) had evi-
dence of emerging dominance of preexisting minority
strains (rising from 3-9% of in pretreatment samples
to 100% in posttreatment samples). Two patients
(P101 and P75) had the same majority variant present
pre- and posttreatment. In P75, a previously unde-
tected minority variant was also detected posttreat-
ment. One patient (P131) had evidence of a persisting
minority variant and in addition, two new variants
were detected. We considered this to be the most likely
case of superinfection in the cohort.
In this study, NGS revealed that persisting strains
were present in 100% of patients with treatment failure.
If Sanger sequencing had been used alone, we would
have detected persisting strains in only 34% of cases. We
have shown that when a new variant is detected using
direct Sanger sequencing, this usually represents the
emergence of a minority variant already present in the
pretreatment sample (Fig. 4). It is likely that such emer-
gent variants represent viral strains with reduced sensitiv-
ity to antiviral medications. We found no evidence of
reinfection in this cohort, despite the likelihood of
ongoing behavioral risk. We cannot, however, exclude
the possibility of patients being reinfected from the same
source, and superinfection could have occurred in as
many as 6/15 (40%) of the patient cohort in whom a
previously undetected (new) variant was found. In three
of these cases (20%), the new variant represented the
majority variant and in three cases (20%), the new vari-
ant was a minority strain. The presence of new variants
in posttreatment samples could also represent previously
undetected minority variants selected by treatment or
compartmentalized strains within different regions of the
liver, lymphocytes, or the central nervous system.10,24-27
The role of compartmentalized virus acting as a reserve
for future viral rebound is, as yet, relatively unexplored.
It has been postulated as a strong and independent pre-
dictor of treatment efficacy.28 Hara et al.29 demonstrated
that in late relapsers, HCV strains could be detected at
low levels in liver biopsies during the aviremic phase, in
keeping with the possibility of compartmentalization in
patients with viral relapse.
8 ABDELRAHMAN ET AL. HEPATOLOGY, Month 2014
Several studies of reinfection following treatment-
induced clearance have previously been limited by incom-
plete longitudinal follow-up and insensitive detection
methods.30 Lambers et al.5 described an alarmingly high
incidence rate of sexually transmitted HCV reinfection of
15.2 per 100 person years among HIV-infected MSM
previously successfully treated for primary HCV infection.
Martin et al.6 also described a high risk of HCV reinfec-
tion among HIV-positive MSM who were either treated
for or who spontaneously cleared initial HCV infection.
In a German PWID, a reinfection rate of 0-4.1/100
person-years has been proposed.31 These studies did not
incorporate data from studies designed to identify mixed
strain infections prior to treatment, nor emergence of
minority variants following treatment. It is likely that the
majority of recorded reinfections were preexisting infec-
tions that became detectable after a dominant strain had
cleared. A limitation of our work is that we did not inves-
tigate late relapse (viral rebound more than 24 weeks after
the end of treatment) in this study; in other HCV popu-
lations, this has been shown to be a result of persistent
infection32; this would be an interesting area of further
Fig. 4. Viral dynamics during
treatment failure.
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study in this population, as it is clear that patients in this
and similar cohorts are at ongoing high risk of reinfec-
tion.18 We propose, however, that the definition of rein-
fection, persisting infection, or superinfection should
always be based on rigorous viral sequencing techniques.
In conclusion, deep sequencing technologies are a
powerful tool for obtaining a more accurate insight
into the dynamics of variants in the HCV quasispecies
in human samples. The detection of multiple geno-
types that have the potential to emerge following treat-
ment may also have implications in the new era of
DAAs when the presence of multiple genotypes and
low-level resistance mutations may impact on treat-
ment success.
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